Severe infection with Fasciola hepatica as the cause of hemorrhagic ascites;Ascite hemorragique revelant une infection massive a Fasciola hepatica

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 10, 1997, Pages 785-788

  Montembault, Sarah ^a   Serfaty, Lawrence ^a   Poirot, Jean Luc ^a   Wendum, Dominique ^a   Penna, Christophe ^a   Poupon, Raoul ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Distomatosis; Fasciola hepatica; Haemorrhagic ascites; Human fasciolasis; Praziquantel; Triclabendazole

Indexed keywords

PRAZIQUANTEL; TRICLABENDAZOLE; ANTHELMINTIC AGENT; ANTIPLATYHELMINTIC AGENT; BENZIMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; ASCITES; CASE REPORT; DISEASE SEVERITY; FASCIOLA HEPATICA; FASCIOLIASIS; HEPATITIS; HUMAN; HYPERGAMMAGLOBULINEMIA; MALE; PERITONITIS; ASCITES FLUID; BLEEDING; PARASITOLOGY; PATHOLOGY;

ADULT; ANTHELMINTICS; ANTIPLATYHELMINTIC AGENTS; ASCITIC FLUID; BENZIMIDAZOLES; FASCIOLIASIS; HEMORRHAGE; HUMANS; MALE; PRAZIQUANTEL;

EID: 0031320831     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Moreau JA, Fernandez J, Recco P, Seguela JP, Frexinos J. Efficacité et tolérance du praziquantel (Biltricide) dans le traitement de la distomatose à Fasciola hepatica. Gastroenterol Clin Biol 1995;19:514-9.
2. Jones EA, Kay JM, Milligan HP, Owens D. Massive infection with Fasciola hepatica in man. Am J Med 1977;63:836-42.
3. Delasalle P, Beytout J, Lambon M, Bommelaer G. Distomatoses: diagnostic et traitement. Rev Prat (Paris) 1990;3:230-8.
4. Catchpole BN, Manc MB, Snow D. Human ectopic fasciolasis. Lancet 1952;2:711-2.
5. Schussele A, Laperrouza C. Les distomatoses hépatiques: à propos de 9 observations personnelles. Schweiz Med Wochenschr 1971;101:1677-87.
6. Crinquette J, Becquet R, Vilain B. Les manifestations respiratoires au cours de la distomatose à Fasciola hepatica. J Fr Med 1965:529-41.
7. Guichard A, Alex R, Paliard P, Moulin G. A propos d'un cas de distomatose hépatique dépistée par une éosinophilie médullaire. Soc Med Hôp Lyon 1959:519-25.
8. Mougeot G. Les distomatoses. Med Chir Dig 1973;2:169-74.
9. Schiapacasse RH, Mohammadi D, Christie AJ. Successful treatment of severe infection with Fasciola hepatica with praziquantel. J Infect Dis 1985;152:1339-40.
10. Hadden JW, Pascarelli EF. Diagnosis and treatment of human fasciolasis. JAMA 1967;202:149-51.
11. Dugernier T, Geubel A, Bigaignon G, Cesbron JY, Coche E. Human fasciolasis: cure by mebendazole. A case report. Gastroenterol Clin Biol 1986;10:513-6.
12. Farag HF, Salem A, El-Hifini SA, Kandil M. Bithionol (Bitin) treatment in established fasciolasis in Egyptians. J Trop Med Hyg 1988;91:240-4.
13. Farag HF, Ragab M, Salem A, Sadek N. A short note of praziquantel in human fasciolasis. J Trop Med Hyg 1986;89:79-80.
14. Ripert CL. Praziquantel and Fasciola hepatica infection. Trans Soc Trop Med Hyg 1990;84:610.
15. Coulaud JP. Actualités dans le traitement des helminthiases. Presse Med 1984;13:2201-5.
16. Wesserly K, Reisching HL, Heinerman M, Stempka R. Human fasciolasis treated with triclabendazole (Fasinex) for the first time. Trans R Soc Trop Med Hyg 1988;82:743-5.
17. Laird P, Boray JC. Human fasciolasis successfully treated with triclabendazole. Aust NZ Med J 1992;22:45-7.
18. Loutan L, Bouvier M, Rojanawisut B, Stadler H, Rouan MC, Buescher G, et al. Single treatment of invasive fasciolasis with triclabendazole. Lancet 1989;1:383.
19. Picot S, Querrec M, Ghez JL, Goullier-Fleuret A, Grillot R, Ambroise-Thomas P. A new report of triclabendazole efficacy during invading phase fasciolasis. Eur J Clin Microbiol Infect Dis 1992;11:2-3.